Filing Flows › Tela Bio (TELA) › Q4 2024
Tela Bio (TELA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 21, 2025
Tela Bio (TELA) reported revenue of $17.6M for the fourth quarter 2024 (Q4 2024), +4% from a year earlier and -7% from the quarter before. Operating margin was -47.3%, net loss $9.2M (52.2% of revenue).
Tela Bio, Q4 2024: revenue $17.6M (+4% year over year), operating margin -47.3%, net loss $9.2M, operating cash flow −$7.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.6M | -7% | +4% |
| Operating profit | −$8.4M | — | — |
| Net earnings | −$9.2M | — | — |
| Operating cash flow | −$7.5M | — | — |
What changed
Revenue was $17.6M in Q4 2024, up 4% year over year and down 7% from the previous quarter.
Gross margin was 63.6%, down 4.8 points from a year earlier. Operating costs exceeded revenue by $8.4M, an operating margin of -47.3%. Operating expenses fell 18% while revenue rose 4%. The quarter ended with a net loss of $9.2M, narrower than the previous quarter's $10.4M loss.
Operating cash flow was −$7.5M. Non-cash charges added back $171K of depreciation and $1.1M of share-based compensation. Working capital and other items added $417K. Capital expenditures of $264K exceeded it, leaving free cash flow of −$7.8M.
Questions
What was Tela Bio's revenue in the fourth quarter 2024?
Tela Bio (TELA) reported revenue of $17.6M for the fourth quarter 2024 (Q4 2024), +4% from a year earlier and -7% from the quarter before.
Was Tela Bio profitable in the fourth quarter 2024?
Operating loss was $8.4M (-47.3% of revenue) and net loss $9.2M.
Source: Tela Bio 10-K on SEC EDGAR.